An alternative synthesis of the non-small cell lung carcinoma drug afatinib (CROSBI ID 288671)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Kovacevic, Tatjana ; Mesic, Milan ; Avdagic, Amir ; Zegarac, Miroslav
engleski
An alternative synthesis of the non-small cell lung carcinoma drug afatinib
Afatinib (BIBW2992, I) is the anticancer drug developed by Boehringer Ingelheim. This work is reporting the synthesis of the afatinib using a new route by Ullmann-Goldberg reaction from corresponding 4-anilinoquinazoline iodide as the last step in the synthesis. This route was not described previously and it could be used for synthesis of afatinib analogs.
afatinib ; alternative synthesis ; cancer
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
59 (47)
2018.
4180-4182
objavljeno
0040-4039
1873-3581
10.1016/j.tetlet.2018.10.026
Povezanost rada
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Farmacija, Interdisciplinarne prirodne znanosti, Kemija